GlassScriptPhysician profile
Ashok Penmetsa
NPI 1669471322
$10,509.77
in general payments reported to CMS, 2019-2025
29 companies · $1,730 in 2025
The $1,730 reported for 2025 was more than what 81% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,881 · 2020: $1,468 · 2021: $1,518 · 2022: $1,388 · 2023: $738 · 2024: $1,786 · 2025: $1,730.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,249 · Travel and Lodging: $5.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,248.97 |
| Travel and Lodging | $5.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,976.02 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $1,563.65 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $1,329.40 | 2019-2024 | Xarelto |
| Scpharmaceuticals INC. | $738.00 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $715.93 | 2019-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $615.54 | 2019-2025 | Jardiance |
| Pfizer INC. | $563.17 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $389.23 | 2021-2025 | Verquvo |
| Edwards Lifesciences Corporation | $310.35 | 2019-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Esperion Therapeutics, INC. | $297.05 | 2020-2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $261.23 | 2021-2025 | |
| Boston Scientific Corporation | $241.48 | 2019-2024 | Watchman Access System |
| E.R. Squibb & Sons, L.L.C. | $238.72 | 2019-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $208.36 | 2020-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Jot Dx, Assurity |
| Amarin Pharma, INC. | $179.17 | 2020-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $156.14 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $139.09 | 2019 | |
| Medtronic Vascular, INC. | $138.94 | 2019 | |
| Abiomed | $120.93 | 2024-2025 | Impella |
| Lexicon Pharmaceuticals, INC. | $111.36 | 2023-2024 | Inpefa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $90.02 | 2023-2025 | Lifevest |
| Amryt Pharma Holdings LTD | $21.19 | 2021 | |
| Philips North America LLC | $20.58 | 2023 | |
| Novo Nordisk INC | $18.77 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $14.58 | 2024 | Arcalyst |
| Glaxosmithkline, LLC. | $14.40 | 2025 | Arexvy, Shingrix |
| Medtronic, INC. | $13.38 | 2021 | |
| Irhythm Technologies, INC. | $13.09 | 2020 | |
| Bardy Diagnostics, INC. | $10.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashok Penmetsa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.